SB202190 (FHPI)

For research use only. Not for use in humans.

目录号：S1077

CAS No. 152121-30-7

SB202190 (FHPI)是一种有效的p38 MAPK抑制剂，靶向作用于p38α/β，无细胞试验中IC50为50 nM/100 nM，有时用于代替SB 203580研究其在体内对SAPK2a/p38的潜在作用。SB202190 可通过诱导自噬和血红素氧化酶1来抑制内皮细胞的凋亡。SB202190可显著抑制Erastin依赖的铁死亡ferroptosis。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1091.41	现货
25mg	RMB 1189.49	现货
100mg	RMB 3017.14	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的SB202190 (FHPI)发表文献110篇：

Cancer Cell, 2019, 35(5):798-815

PubMed: 31031016 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Nat Biotechnol, 2017, 35(6):577-582

PubMed: 28459450 ( click the link to review the publication )

Nat Biotechnol, 2016, 34(11):1161-1167

PubMed: 27723727 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(7):428-36

PubMed: 23685672 ( click the link to review the publication )

Carcinogenesis, 2021, bgab002

PubMed: 33417668 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Biosci Rep, 2021, 41(3)BSR20192668

PubMed: 33616153 ( click the link to review the publication )

J Mol Med (Berl), 2021, 10.1007/s00109-021-02047-5

PubMed: 33611659 ( click the link to review the publication )

Redox Biol, 2020, 28:101445

PubMed: 32037305 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):771

PubMed: 32943609 ( click the link to review the publication )

Cells, 2020, 13;9(5) pii: E1209

PubMed: 32414111 ( click the link to review the publication )

Cells, 2020, 28;9(4) pii: E822

PubMed: 32231153 ( click the link to review the publication )

J Neuroinflammation, 2020, 17(1):364

PubMed: 33261639 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:6584059

PubMed: 33274004 ( click the link to review the publication )

Cell Discov, 2020, 6:35

PubMed: 32550000 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(5):3203-3216

PubMed: 32053272 ( click the link to review the publication )

Eur J Immunol, 2020, 10.1002/eji.201948363

PubMed: 32022930 ( click the link to review the publication )

Sci Rep, 2020,

PubMed: 32884042 ( click the link to review the publication )

Front Pharmacol, 2020, 11:758

PubMed: 32523533 ( click the link to review the publication )

Chem Biol Interact, 2020, 317:108944

PubMed: 31935364 ( click the link to review the publication )

Int J Environ Health Res, 2020, 10.1080/09603123.2020.1739236

PubMed: 32191530 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )
J Thorac Dis, 2020, 12(7):3764-3773

PubMed: 32802455 ( click the link to review the publication )

J Exp Med, 2020, 217(2)

PubMed: 31753849 ( click the link to review the publication )

J Dev Biol, 2020, 8(3):E12

PubMed: 32660129 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-0963-y

PubMed: 32606358 ( click the link to review the publication )

Cell Prolif, 2020, e12869

PubMed: 32597573 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2020, 10(4):779-796

PubMed: 32561494 ( click the link to review the publication )

Mol Cell, 2019, 76(6):965-980

PubMed: 31588023 ( click the link to review the publication )

Theranostics, 2019, 9(13):3879-3902

PubMed: 31281520 ( click the link to review the publication )

Theranostics, 2019, 9(17):5065-5084

PubMed: 31410202 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):718

PubMed: 31558705 ( click the link to review the publication )

Cells, 2019, 8(7)

PubMed: 31248002 ( click the link to review the publication )

Cells, 2019, 8(9)

PubMed: 31461951 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Neoplasia, 2019, 22(1):1-9

PubMed: 31751859 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.29305

PubMed: 31612516 ( click the link to review the publication )

Antiviral Res, 2019, 170:104572

PubMed: 31376425 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(2):920-933

PubMed: 30394679 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(4)

PubMed: 30781441 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31117181 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):19409

PubMed: 31857650 ( click the link to review the publication )

J Pharmacol Exp Ther, 2019, 370(2):219-230

PubMed: 31189728 ( click the link to review the publication )

Life Sci, 2019, 231:116550

PubMed: 31185235 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )
Mol Immunol, 2019, 111:162-171

PubMed: 31063937 ( click the link to review the publication )

J Biol Eng, 2019, 13:82

PubMed: 31709009 ( click the link to review the publication )

J Biol Eng, 2019, 13:36

PubMed: 31061676 ( click the link to review the publication )

Microb Pathog, 2019, 130:204-212

PubMed: 30885749 ( click the link to review the publication )

J Physiol Biochem, 2019, 75(4):475-487

PubMed: 31399951 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Sci Signal, 2018,

PubMed: 29511118 ( click the link to review the publication )

EBioMedicine, 2018, 36:497-507

PubMed: 30190207 ( click the link to review the publication )

Front Immunol, 2018, 9:1051

PubMed: 29896191 ( click the link to review the publication )

J Virol, 2018, 92(4)e01463-17

PubMed: 29167338 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):271-283

PubMed: 29090321 ( click the link to review the publication )

Sci Rep, 2018, 8(1):5074

PubMed: 29568077 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:9793845

PubMed: 30693038 ( click the link to review the publication )

Am J Transl Res, 2018, 10(8):2555-2566

PubMed: 30210692 ( click the link to review the publication )

Infect Immun, 2018, 22;86(9):e00233-18

PubMed: 29986890 ( click the link to review the publication )

Eur J Pharmacol, 2018, 838:129-137

PubMed: 30196111 ( click the link to review the publication )

Toxicon, 2018, 155:1-8

PubMed: 30290166 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2018, 5(3):333-352

PubMed: 29552622 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Biomaterials, 2017, 128:44-55

PubMed: 28288348 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )
Sci Rep, 2017, 7:43242

PubMed: 28266583 ( click the link to review the publication )

Sci Rep, 2017, 7(1):7442

PubMed: 28785085 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 323:44-52

PubMed: 28341536 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:61-69

PubMed: 28315487 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 5(2):113-130

PubMed: 29693040 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2017, 4(1):165-182

PubMed: 29204504 ( click the link to review the publication )

Clin Cancer Res, 2016, 10.1158/1078-0432.CCR-15-2242

PubMed: 27297582 ( click the link to review the publication )

J Dent Res, 2016, 95(7):769-75

PubMed: 26961489 ( click the link to review the publication )

Int J Mol Sci, 2016,

PubMed: 27782092 ( click the link to review the publication )

Sci Rep, 2016, 6:30904

PubMed: 27485764 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2016, 303:79-89

PubMed: 27174766 ( click the link to review the publication )

J Cancer, 2016, 7(8):900-9

PubMed: 27313779 ( click the link to review the publication )

J Diabetes Res, 2016, 2016:9073037

PubMed: 27635403 ( click the link to review the publication )

Oncol Rep, 2016, 35(5):3009-17

PubMed: 26986870 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Neurochem Res, 2016, 41(8):1969-81

PubMed: 27068033 ( click the link to review the publication )

Mol Med Rep, 2016, 14(2):1430-8

PubMed: 27278862 ( click the link to review the publication )

Oncotarget, 2016, 7(25):37407-37419

PubMed: 27270648 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(12):1578-90

PubMed: 26376801 ( click the link to review the publication )

Inflamm Bowel Dis, 2015, 21(3):496-506

PubMed: 25647156 ( click the link to review the publication )
Cell Transplant, 2015, 24(3):573-88

PubMed: 25654487 ( click the link to review the publication )

Nat Commun, 2014, 5:3479

PubMed: 24632940 ( click the link to review the publication )

Cell Rep, 2014, 8(4):1037-48

PubMed: 25127139 ( click the link to review the publication )

Chem Res Toxicol, 2014, 27(9):1575-85

PubMed: 25148906 ( click the link to review the publication )

BMC Cancer, 2014, 14:325

PubMed: ( click the link to review the publication )

Life Sci, 2014, 108(2):63-70

PubMed: 24857982 ( click the link to review the publication )

Int Immunopharmacol, 2014, 24(1): 50-58

PubMed: 25479727 ( click the link to review the publication )

J Cell Biochem, 2014, 115(5):874-88

PubMed: 24375433 ( click the link to review the publication )

Cell Transplant, 2014, 23(4-5):641-56

PubMed: 24816456 ( click the link to review the publication )

Mol Biosyst, 2014, 10(3):605-12

PubMed: 24413303 ( click the link to review the publication )

Mol Cell Biochem, 2014, 397(1-2):131-8

PubMed: 25138701 ( click the link to review the publication )

Anticancer Agents Med Chem, 2014, 14(8):1154-60

PubMed: 24934165 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

J Biol Chem, 2010, 285(43):32824-33

PubMed: 20729213 ( click the link to review the publication )

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

产品描述

特性

SB 202190 与SB 203580极为相似。

靶点

Ferroptosis ^[11] ()	p38α ^[1] (Cell-free assay)	p38β ^[1] (Cell-free assay)
	50 nM	100 nM

体外研究

SB 202190显著抑制内源本底和和抗Fas抗体诱导的MAPKAPK 2活性，且抑制效果呈剂量依赖性。SB 202190本身就足以诱导Jurkat细胞和Hela细胞的死亡：通过激活CPP 32样半胱氨酸蛋白酶，可阻断Bcl - 2的表达。p38β可减轻而p38α可加剧由SB 202190诱导的细胞凋亡^[2]。在HaCaT细胞中SB 202190强烈抑制由紫外线诱导的cox - 2蛋白表达和 mRNA水平^[3]。用SB 202190处理肾小管上皮细胞（正常大鼠k肝脏-52E），可将由白蛋白引发的炎症（单核细胞趋化蛋白-1，MCP - 1）或肿瘤生长因子β-1（TGFβ-1）引发的原纤维化（原骨胶原I a1，procollagen-i alpha1）相关基因降低50%^[4]。SB 202190处理A549细胞，可诱导JNK磷酸化（该磷酸化效应呈时间和剂量依赖性）、转录因子ATF - 2磷酸化，并增加AP – 1与DNA的结合^[6]。SB 202190处理促进THP-1和MV4-11细胞的生长。SB 202190可提高c-Raf 和ERK（细胞外信号调节激酶）磷酸化，暗示由SB 202190诱导的白血病细胞增殖过程有Ras-Raf-MEK-mitogen激活的MAPK通路的参与^[7]。

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HCT-116	NFTBXmRHfW6ldHnvckBCe3OjeR?=	Ml[5NlUh\|ryP	MYWzNEBucW5?	MVrEUXNQyqB?	M2DlUYF1fGWwdXH0[ZMhfGinIH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbjDv[kBpSkRvMjDpckBz\XOyb37zbZZmKHSxIFTB	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ{M{K1NUc,OjZ{MkOyOVE9N2F-
MDA-MB-231	MlvRSpVv[3Srb36gRZN{[Xl?	NH\Te48zKM7:TR?=	NWThWllSOjRiaB?=		M2niV4xme3OnbnXzJGNEVDJiaX7keYN1cW:wIHL5JHRPTs7z	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjFyMEi0PEc,OjZzMEC4OFg9N2F-
rBMSCs	MV\GeY5kfGmxbjDBd5NigQ>?	NXvsc5pLOTBizszN	Mo\MNk42KGh?		NVzYfJVs\GWycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd25ib3[gSXJMKGGwZDDwN\|g>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3M{K2Okc,OjZyNUOyOlY9N2F-
MG63	NFvCWG9HfW6ldHnvckBCe3OjeR?=	NIPwe2YyOC9{MD:zNEDPxE1?	M1TPZ\|I1KGh?		NIHQPZV{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczD0bIUhdGW4ZXygc4YheGixc4Doc5J6dGG2ZXSgdFM5KGmwZIXj[YQh[nliQ3TDcFIhcW5iYTDjc45k\W62cnH0bY9vKC2mZYDlcoRmdnRibXHucoVz	NV\yXJB7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5PVg{OTJpPkK1PVk5OzF{PD;hQi=>
MG63	MlnVRZBweHSxc3nzJGF{e2G7	M{HuclExNzJyL{OwJO69VQ>?	M1jVRVI1KGh?		NGTqUmN{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnZDD0bIUh[XCxcITvd4l{KHKjdHWgc4YhVUd4MzDpcoR2[2WmIHL5JGNlS2x{	NHnmV3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5PFMyOid-MkW5PVg{OTJ:L3G+
HTSMCs	MnKxSpVv[3Srb36gRZN{[Xl?	MWGwMlEwOS9zMDFOwG0>	NEfGZ3AyKGh?		MX3pcohq[mm2ZXSgR29TVS1{LXnu[JVk\WRiSF:tNUBxem:2ZXnuJIxmfmWuczDhcoQhdVKQQTDlfJBz\XO\|aX;u	NWnYfGpMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NlE1PjRpPkK1PVIyPDZ2PD;hQi=>
MIA PaCa-2	NXn2ZVR7TnWwY4Tpc44hSXO\|YYm=	NFfqWokzOMLizszN	M2LJVlI1KGh?		MkPBdoVlfWOnZDDsZYN1[XSnIHHjZ5VufWyjdHnvckBqdiClb33ibY5ifGmxbjD3bZRpKGKxdHigNk1FTyCjbnSgSE1idGyxc3ZCpC=>	M{\DNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
MIA PaCa-2	NF7xZ3BHfW6ldHnvckBCe3OjeR?=	NVPOT\|lROjEEoN88US=>	M{nqeFI1KGh?		MmLodoV{fWy2czDpckBiKG2xZHXzeEBqdmirYnn0bY9vKG:oIFjJSk0y\|rFicILveIVqdiCjY3P1cZVt[XSrb36=	NEDqW5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
BxPC-3	NWLrbpAxTnWwY4Tpc44hSXO\|YYm=	MYeyNOKh\|ryP	MnHCNlQhcA>?		NVXSNmFvemW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	M4DHXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEi4OFg6Lz5{NUi4PFQ5QTxxYU6=
AsPC-1	NVXPTmhWTnWwY4Tpc44hSXO\|YYm=	NIP0[3IzOMLizszN	M4r1XVI1KGh?		NYjPTJZ7emW\|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44>	NYOzcFBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
MIA PaCa-2	M{PJcmZ2dmO2aX;uJGF{e2G7	MVKyNOKh\|ryP	MnzCNlQhcA>?		MYnlcohidmOnczDjcIVifmGpZTDv[kBRSVKSIIfo[Y4h[2:vYnnu[YQhf2m2aDDncJVkd3OnIHHuZYxw\3N?	NXr1OGhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
MIA PaCa-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPIVIkzOMLizszN	NV\qV2dROiCq		Mk\3d4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm	NU\5TIl{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
BxPC-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjmRlczOMLizszN	NFnsflQzKGh?		M3jFZ5NmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>?	NYTTSpN1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4PFg1QDlpPkK1PFg5PDh7PD;hQi=>
AsPC-1	NYG3bmdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlraNlDDqM7:TR?=	MmXINkBp		NU\kVpVue2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	MnPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEi0PFkoRjJ3OEi4OFg6RC:jPh?=
HEY	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXiyNOKh\|ryP	NWTvfFRzOiCq		NWnaXpc2e2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NGLPRpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
OVCAR-3	NXHqeYF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILLN\|gzOMLizszN	M1njSlIhcA>?		NW\aXYlbe2Wwc3n0bZpmeyClZXzsJIxqdmW\|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On	NHK5OmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
SK-OV-3	M4j3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jIRlIxyqEQvF2=	MomwNkBp		NHrjWpJ{\W6\|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V?	NHrmSVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4PFQ5QSd-MkW4PFg1QDl:L3G+
MH7A	M3Sxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVOyOEBp		M3q2[pJmcW6ob4Lj[ZMhfGinIHnubIljcXSxcomg[YZn\WO2czDv[kBZSU5?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh4Mkm2Okc,OjV6NkK5OlY9N2F-
MH7A	NF3p[I5CeG:ydH;zbZMhSXO\|YYm=	NFT1cGszPSEQvF2=	NXf3d2JSOjRiaB?=		NVry[ZZjemW4ZYLz[ZMh[2WubDDjfYNt\SCjcoLld5QhcW6mdXPl[EBjgSC[QV6gZY5lKGOjdYPl[EBieG:ydH;zbZMhd2ZiY3XscJMhfmmjIHHjeIl3[XSrb36gc4YhUk6N	MoDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NkK5OlYoRjJ3OE[yPVY3RC:jPh?=
SCC25	Mmr1SpVv[3Srb36gRZN{[Xl?	NWr4UJBpOjBizszN	M3zPXlI1KGh?		MkjrbY5kemWjc3XzJIF2fG:yaHHnfUBt\X[nbB?=	NHm4WG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUizOFQxOCd-MkW4N\|Q1ODB:L3G+
HaCaT	NULMNm57TnWwY4Tpc44hSXO\|YYm=	MkDpOUDDvU1?	M{XqN\|I1KGh?		MULpcohq[mm2czDJSm4u\|rNvaX7keYNm\CCFQ1yyNkBxem:mdXP0bY9vKGyndnXsdy=>	NVuxPWdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q{PTNpPkK1PFM1OzV\|PD;hQi=>
HaCaT	M{jHXmZ2dmO2aX;uJGF{e2G7	NV;XenJ[PSEEtV2=	NEHNeIYzPCCq		M{XoN4lvcGmkaYTzJGlHVi4QsT3pcoR2[2WmIFPDUFIzKHC{b3T1Z5Rqd25ibHX2[Yx{	NV3KboZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4N\|Q{PTNpPkK1PFM1OzV\|PD;hQi=>
HPAEpiCs	NGHpPFBHfW6ldHnvckBCe3OjeR?=	NXzTe3RlOS9\|L{GwJO69VQ>?	MmC1NUBp		MVLy[YR2[2W\|IGOxVE1qdmS3Y3XkJGlESU1vMTDwdo91\WmwIHHu[EBuWk6DIHX4dJJme3Orb36gZY5lKHC{b33veIVzKGGldHn2bZR6	MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5M{S5NFAoRjJ3N{O0PVAxRC:jPh?=
HPAEpiCs	M1:3WGZ2dmO2aX;uJGF{e2G7	M4DGWVEwOy9zMDFOwG0>	MX:xJIg>		M4TseIlvcGmkaYTzJHMyWC2\|dHnteYxifGWmIFHreEBxcG:\|cHjvdplt[XSrb36gJOKh	NW\6c\|RjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Q6ODBpPkK1O\|M1QTByPD;hQi=>
HPAEpiCs	MmPXSpVv[3Srb36gRZN{[Xl?	Mo[5NU8{NzFyIN88US=>	MYKxJIg>		NH75eYlqdmirYnn0d{BUOVBidHnt[U1l\XCnbnTlcpRtgSC\|dHnteYxifGWmIHOtTpVvKHCqb4PwbI9zgWyjdHnvci=>	NXH1dINRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3N\|Q6ODBpPkK1O\|M1QTByPD;hQi=>
K562	M4m3fmZ2dmO2aX;uJGF{e2G7	MnTjNVDDqM7:TR?=	MlT4NeKhcA>?	M1jSe2ROW09?	Ml3JbY5pcWKrdIOgdZVqdmGlcnnu[U1qdmS3Y3XkJJA{QCCPQWDLJJBpd3OyaH;yfYxifGmxbh?=	NUHxPJdIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFQxPDNpPkK1Olg1ODR\|PD;hQi=>
PANC-1	NYjEZ4Z6TnWwY4Tpc44hSXO\|YYm=	M3TtR\|ExKM7:TR?=	NY\6d29bOSCq		M4XteIVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi	NWDZcFZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjJpPkK1OlMzOjJ{PD;hQi=>
BxPC-3	M{frfGZ2dmO2aX;uJGF{e2G7	M{\IRVExKM7:TR?=	NVnqfFdrOSCq		Mluz[Y5p[W6lZYOgeIhmKGG3dH;wbIFocWNiZX\m[YN1yqB?	NWjOS\|VDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|IzOjJpPkK1OlMzOjJ{PD;hQi=>
K562	NGL1OIhHfW6ldHnvckBCe3OjeR?=	NYqy[WtiOC5{NT2xJO69VQ>?	MXuyOEBp		NHL6bpp{fXCycnXzd4V{KHKnc4\ldoF1em:uLXnu[JVk\WRiSELBXEBxcG:\|cHjvdplt[XSrb36=	NUjaRnRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2NVk{QTJpPkK1OlE6Ozl{PD;hQi=>
THP-1	NUDkO4lyTnWwY4Tpc44hSXO\|YYm=	NF;vTFM2KML3TR?=	NGL2TXgzKGh?		NHPIUWd{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgd4VkemW2aX;uJI9nKEmOLUJOtUBqdmS3Y3XkJIJ6KDJ5T1jDbI9tKHCudYOgSnNNNTIEoB?=	NGGzOJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW5PFY3OSd-MkW1PVg3PjF:L3G+
WB	MYDGeY5kfGmxbjDBd5NigQ>?	NWDHNo1jOjEkgJpOwG3DqA>?	MVWzNQKBkW2rbh?=		MnHM[IVkemWjc3XzJJRp\SCOUGOtJI9zKEyWQT3pcoR2[2WmIFnMMVYh[W6mIGTOSk3PucLicILv[JVkfGmxbh?=	M3G3bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUOwOlgzLz5{NUWzNFY5OjxxYU6=
RAW 264.7	NF71eIRHfW6ldHnvckBCe3OjeR?=	NIXlcXQyOMLizszN	NEHLXYM{OOLCiX3pci=>		M2T2dolv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O\|wrC=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4MUO5PUc,OjV2NkGzPVk9N2F-
RAW 264.7	M2P0[2Z2dmO2aX;uJGF{e2G7	NFnmT4wyOMLizszN	NYfJ[WJXOzEkgJntbY4>		NEfwRVlifHSnboXheIV{KHSqZTDl[oZm[3S\|IH;mJG9RTyCxbjDvd5Rmd2OuYYP0JJJmfHKjY4Tpc44>	NWXoOmNmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlE{QTlpPkK1OFYyOzl7PD;hQi=>
HaCaT	NUfVPIdJTnWwY4Tpc44hSXO\|YYm=	MVq0NOKh\|ryP	MoHXN{0zPCCq	NHHSZVZFVVOR	MWHy[YR2[2W\|IITo[UBi[2O3bYXsZZRqd25ib3[gXm8uOQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR\|NUS4OUc,OjV2M{W0PFU9N2F-
H9c2	MX;GeY5kfGmxbjDBd5NigQ>?	NY\kSJFpPTEEoN88UeKh	Mlv3NVIhcA>?		NU\5RmRremWmdXPld{BNTEhicnXs[YF{\SCjbnSgUW1RKGyxc4O=	NHXmUZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK0OVgyQCd-MkWyOFU5OTh:L3G+
HSCs	M1nqNmFxd3C2b4Ppd{BCe3OjeR?=	Mlq5NlUh\|ryP	NVHTS5R[OjUEoHi=		NVzhOXZYe2mpbnnmbYNidnSueTDheJRmdnWjdHXzJHRINWmwZIXj[YQh[WO2aY\heIVlKEiVQ4OgZZBweHSxc3nz	NX\vR4luRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OlE6PTBpPkK0PVYyQTVyPD;hQi=>
THP-1	NHHtcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPxUZc4OiCq	NWjpdGNNTE2VTx?=	M4fIdWlEPTB;ND63{txO	M2j5NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEG1NFg4Lz5{NEixOVA5PzxxYU6=
MDDCs	NF25eYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnH6O\|IhcA>?	MojmSG1UVw>?	MXXJR\|UxOi55zszN	MknBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6MUWwPFcoRjJ2OEG1NFg4RC:jPh?=
MDDCs	NU\zS\|RLTnWwY4Tpc44hSXO\|YYm=	NU\XZ5AzOC1zNTFOwG0>	Mmn5OFghcA>?	NV6zeWxLTE2VTx?=	NH;WWVF{fXCycnXzd4V{KEmITj5OtUBidmRiSWCtNVAheHKxZIXjeIlwdsLi	NFTMVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEixOVA5Pyd-MkS4NVUxQDd:L3G+
MDDCs	M1PHPWZ2dmO2aX;uJGF{e2G7	M4nYOFAuOTVizszN	Mm\rOFghcA>?	M4XI[mROW09?	NWHxOnI6cW6qaXLpeJMhVUmSLUHhMEBOUVBvMXKgZY5lKFKDTmTFV{Bxem:mdXP0bY9v	NUGzR\|lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NVUxQDdpPkK0PFE2ODh5PD;hQi=>
MDDCs	M{TnUGZ2dmO2aX;uJGF{e2G7	MU[xNEDPxE1?	MmS5N{42KGh?	MUXEUXNQ	MnzEZoxw[2u\|IFXCU3YhT1BuIHL1eEBvd3RiVmPWJGchdWWmaXH0[YQh\W62comgbY51dyCqdX3hckBOTESFcx?=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDhzNUC4O{c,OjR6MUWwPFc9N2F-
macrophages	MXXGeY5kfGmxbjDBd5NigQ>?	MYOx5qCK\|ryP	NWHEOIQ5PC534pEJbC=>		NHjTOIJkd22ybHX0[Yx6KGmwaHnibZR{KE2WLVnJTU1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiTl[t{tpD	NUnyTZBCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4NFg3OzNpPkK0PFA5PjN\|PD;hQi=>
PDL	NEKxeHZHfW6ldHnvckBCe3OjeR?=	MWKyNOKh\|ryPwrC=	NHTqbYo{OCCvaX6=	M4XhemROW09?	MWLzbYdvcW[rY3HueIx6KGmwaHnibZR{KHSqZTD0[Y5{cWynIH\vdoNmNW2nZHnheIVlKEKPUD2yJIV5eHKnc4Ppc44>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV4MUC4NUc,OjR3NkGwPFE9N2F-
AGS	NUX5SZkxTnWwY4Tpc44hSXO\|YYm=	NUO5VWpRPSEQvF2=	NX65b416OzBibXnu		M3\5d5N2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v	M4HrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUS3PFc5Lz5{NEW0O\|g4QDxxYU6=
H520	M1jxVWZ2dmO2aX;uJGF{e2G7	NEH1eo4yOMLiwsXN	M{[4SVEhcA>?	MXLEUXNQ	NGD3[nNl\WO{ZXHz[ZMhfGinIIDlcYV1emW6ZXStbY5lfWOnZDDNV2gzKG2UTlGgZY5lKHC{b4TlbY4hdGW4ZXzz	NFXsTFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H1703	MnjKSpVv[3Srb36gRZN{[Xl?	NInBZ\|AyOMLiwsXN	MkPtNUBp	NVv2T5h2TE2VTx?=	NWXVNGpH\GWlcnXhd4V{KHSqZTDw[Y1mfHKneHXkMYlv\HWlZXSgUXNJOiCvUl7BJIFv\CCycn;0[YlvKGyndnXsdy=>	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H520	MXHGeY5kfGmxbjDBd5NigQ>?	MYexNOKhyrWP	Mlu1NVIhcA>?	NH3yZ\|ZFVVOR	MVTpcohq[mm2czDw[Y1mfHKneHXkMYVtcWOrdHXkJG1UUDJicILveIVqdiC\|dHHibYxqfHl?	NEnGeVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWzNFQ4PSd-MkS1N\|A1PzV:L3G+
H1703	MoX2SpVv[3Srb36gRZN{[Xl?	MX:xNOKhyrWP	NYL3Onp7OTJiaB?=	MWXEUXNQ	M2TldIlvcGmkaYTzJJBmdWW2cnX4[YQu\WyrY3n0[YQhVVOKMjDwdo91\WmwIIP0ZYJqdGm2eR?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV\|MES3OUc,OjR3M{C0O\|U9N2F-
H520	NHj6UVBHfW6ldHnvckBCe3OjeR?=	NVT2d4JiOTEEoNM1US=>	NIP3cpc3KGh?	NYm2VlNlTE2VTx?=	NHzK[Xl{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhdGW4ZXzzJI9nKHWkaYH1bZRqdi2lb37qeYdifGWmIF3TTFIhcW5icHXt[ZRz\XinZD30doVifGWmwrDj[YxtKGyrbnW=	NWLWc45GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1N\|A1PzVpPkK0OVMxPDd3PD;hQi=>
H1703	NX;4ZXl{TnWwY4Tpc44hSXO\|YYm=	NV7mUoljOTEEoNM1US=>	NYnk[pFnPiCq	NWPzWoZYTE2VTx?=	NXq5dGw3e2mpbnnmbYNidnSueTDpcoNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iC3YnnxeYl1cW5vY3;ubpVo[XSnZDDNV2gzKGmwIIDlcYV1emW6ZXSteJJm[XSnZNMgZ4VtdCCuaX7l	M1fyVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUOwOFc2Lz5{NEWzNFQ4PTxxYU6=
MC3T3-E1	M1LDfGZ2dmO2aX;uJGF{e2G7	MVuwMlMwOy9\|MDFOwG0>	NYTxboROOSCq		M{TwWYF1fGWwdXH0[ZMhXE6ILd8xMYlv\HWlZXSgUW1RNTliZYjwdoV{e2mxbjDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nctMg	MmH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEK2PVYoRjJ2NUCyOlk3RC:jPh?=
MC3T3-E1	NIHMU49HfW6ldHnvckBCe3OjeR?=	MUmzNEDPxE1?	MkjrNUBp		NYjVS4hF[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	MoHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEK2PVYoRjJ2NUCyOlk3RC:jPh?=
HUVECs	NYPRcGs5TnWwY4Tpc44hSXO\|YYm=	NXfVdGtrOTEEoNM1US=>	NUG2XYc5OSCq		MlqwbY5pcWKrdIOgWG5HNc7zLXnu[JVk\WRiQ2jDUFEheHKxZIXjeIlwdg>?	NY[w[VljRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PFc6PjRpPkK0OFg4QTZ2PD;hQi=>
AGS	NXyyRW15TnWwY4Tpc44hSXO\|YYm=	NYTBSWZIOTEEoNM1US=>	NHnZOpU{OMLibXnu		MmfnbY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh?	Mn\LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	NU\oOZZpTnWwY4Tpc44hSXO\|YYm=	NHjSeYcyOMLiwsXN	NVzJZYQ{OzEEoH3pci=>		Mkf6bY5pcWKrdIOgTWwuOc7{LXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOzh?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
AGS	M1:zb2Z2dmO2aX;uJGF{e2G7	NFPMToMyOMLiwsXN	MYWzNOKhdWmw		NF3wSIdifHSnboXheIV{KEmOLUJOtk1qdmS3Y3XkJGdCKGOnbHygcYloemG2aX;uJIFv\CCrbo\hd4lwdg>?	MnvMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	M4TGcWZ2dmO2aX;uJGF{e2G7	M{HSSVExyqEEtV2=	MYezNOKhdWmw		MXHheJRmdnWjdHXzJGlNNTIQsj3pcoR2[2WmIFfBJINmdGxibXnndoF1cW:wIHHu[EBqdn[jc3nvci=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
AGS	MVvGeY5kfGmxbjDBd5NigQ>?	NWfabI9IOTEEoNM1US=>	MkHFN\|DDqG2rbh?=		NV3SdGpse2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgTYwuOc7{LXnu[JVk\WRiTV3QNkBidmRiTV3QPUBuWk6DIHX4dJJme3Orb36=	MorFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2N{m2PFEoRjJ2NEe5OlgyRC:jPh?=
MKN-45	MUHGeY5kfGmxbjDBd5NigQ>?	M{nrW\|ExyqEEtV2=	Mn7QN\|DDqG2rbh?=		MUHzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR5OU[4NUc,OjR2N{m2PFE9N2F-
DCs	M{T4bWZ2dmO2aX;uJGF{e2G7	MlGxNlDDqM7:TR?=	MV[xxsBp		Mnfy[IVkemWjc3XzJGlNNTF{IIDyc4R2[3Srb36=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR\|NE[zOkc,OjR2M{S2N\|Y9N2F-
HUVEC	M{jOW2Z2dmO2aX;uJGF{e2G7	MlPONlAh\|ryvwrC=	M1XaOVUhcA>?	MXrEUXNQ	Ml7GdoVlfWOnczDjfZRwc2mwZTDlfJBz\XO\|aX;uJIxmfmWuczDpckBiKGOxbnPlcpRz[XSrb36t[IVx\W6mZX70JI1idm6nch?=	NY\LVHlZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxPFkxPjJpPkK0NVg6ODZ{PD;hQi=>
A 549	Ml25SpVv[3Srb36gRZN{[Xl?	NXH3dFNEPTBizszN	NW\KRlhjOSCq		NVm2NHBO\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDJUE05yqB?	M2nyUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUe5Olg5Lz5{NEG3PVY5QDxxYU6=
H520	MlzvSpVv[3Srb36gRZN{[Xl?	NWP3bJN7PS9zMDFOwG0>	NF\KU4kyKGh?	MmfsSG1UVw>?	MmLC[IVkemWjc3XzJG1UUDJicILveIVqdiCjczD3[YxtKGG\|IH3SUmEhdGW4ZXzzJIlvKGenZnn0bY5q[i2neIDvd4VlKGOnbHy=	NIHCOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEGzPFkxOyd-MkSxN\|g6ODN:L3G+
H1703	MUDGeY5kfGmxbjDBd5NigQ>?	Mmq2OU8yOCEQvF2=	M1TySVEhcA>?	NWrCT2NCTE2VTx?=	M37JV4Rm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs	MonqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzM{i5NFMoRjJ2MUO4PVA{RC:jPh?=
H520	NWTmbG5HTnWwY4Tpc44hSXO\|YYm=	MkKyNVDDqML3TR?=	NGnLSZYyOiCq	NU\Veng2TE2VTx?=	M{H0UYRm[3KnYYPld{BOW0h{IH3SUmEh[W6mIIDyc5RmcW5ic4ThZoltcXS7IHnuJIdm\mm2aX7pZk11emWjdHXkJG5US0yFIHPlcIx{	NVW3fYZuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxN\|g6ODNpPkK0NVM5QTB\|PD;hQi=>
H1703	Ml;FSpVv[3Srb36gRZN{[Xl?	MU[xNOKhyrWP	NVT3XnFGOTJiaB?=	Ml7ISG1UVw>?	MYXk[YNz\WG\|ZYOgUXNJOiCvUl7BJIFv\CCycn;0[YlvKHO2YXLpcIl1gSCrbjDn[YZqfGmwaXKteJJm[XSnZDDOV2NNSyClZXzsdy=>	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF\|OEmwN{c,OjRzM{i5NFM9N2F-
MCF-7	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\CVnkyOMLizszN	Ml7lNlTDqGh?		NYfwPWRZcW6qaXLpeJMhfGinIFPSNVA5NWmwZIXj[YQh[2WubDDk[YF1cA>?	NWLVOVA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlg5PTNpPkK0NVI5QDV\|PD;hQi=>
HPAEpiCs	MUHGeY5kfGmxbjDBd5NigQ>?	NVq1UXk6OC5zL{GvNVAh\|ryP	Mk\DNUBp		NUG3UXh4cW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgZ3BNSTMEoIDyc5RmcW5iYX7kJI1TVkFiZYjwdoV{e2mxbh?=	NV\OO2dMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOlkyPThpPkK0NFY6OTV6PD;hQi=>
podocytes	NYfHb4pFTnWwY4Tpc44hSXO\|YYm=	MWexNOKh\|ryP	MkPMNUBp		MknIbY5pcWKrdIOgWGdH\|rJzLXnu[JVk\WRiYXP0bZZifGmxbjDv[kBxOziPQWDLJIFv\CCHcnuxM\|LDqA>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB\|NkKxNkc,OjRyM{[yNVI9N2F-
MCF-7	MnrFSpVv[3Srb36gRZN{[Xl?	M3PS[\|ExyqEQvF2=	MnvYNUBp	MWXEUXNQ	Ml30doVlfWOnczD0bIUhX0FvaX7keYNm\CCyaH;zdIhwenmuYYTl[EBxOzhiTVHQTy=>	NH;i[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxPVA6OCd-MkSwNVkxQTB:L3G+
MCF-7	MWXGeY5kfGmxbjDBd5NigQ>?	M2WzS\|ExyqEQvF2=	M1PXW\|I1KGh?	NHzh[oZFVVOR	NXXmTmFMcW6lcnXhd4V{KHSqZTDXRU1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDBzOUC5NEc,OjRyMUmwPVA9N2F-
HAPI	NWH0WZZkTnWwY4Tpc44hSXO\|YYm=	Mm\mNVAwOjBxNEFCpO69VQ>?	MlPYNUBp		MUTpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>?	M1X6e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[5NVIxLz5{M{m2PVEzODxxYU6=
HAPI	MWPGeY5kfGmxbjDBd5NigQ>?	NIG5R2YzOMLizszNxsA>	MmjKNUBp	MmToSG1UVw>?	M3ixdoF1fGWwdXH0[ZMhXEOGRD3pcoR2[2WmIHHjeIl3[XSrb36gc4YhcU6RUzDhcoQheHKxZIXjeIlwdg>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4OUGyNEc,OjN7NkmxNlA9N2F-
HepG2	NGfzTGtHfW6ldHnvckBCe3OjeR?=	MlPDN\|UxKG6P	NE\MSnAzPCCq		MUDpcohq[mm2czD0bIUh\GWpdXXsbY4ucW6mdXPl[EBi[3SrdnH0bY9vKG:oIICzPG1CWEt?	NWrYbYVmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5N\|MyQThpPkKzPVM{OTl6PD;hQi=>
AGS	NVjHNmpRTnWwY4Tpc44hSXO\|YYm=	M1rnc\|ExyqEQvF2=	MkLVN\|AhdWmw		MlTHbY5pcWKrdIOgZ4F{eGG\|ZT2zJIFkfGm4YYTpc44h[W6mIHnubIljcXSrb36gc4YhTVKN	Mn\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NUC5PVQoRjJ\|OEWwPVk1RC:jPh?=
HepG2	NUD2[IU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\aSlAuPTBizszN	NXPTbGE3PDhiaB?=		M1nFVolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzhyN{WwPEc,OjN6MEe1NFg9N2F-
BEL7404	NEO4TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnvNE02OCEQvF2=	Mnu5OFghcA>?		NF\2b\|ZqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NYHVPIpXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NFc2ODhpPkKzPFA4PTB6PD;hQi=>
HL7702	M{S5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrmRW8xNTVyIN88US=>	MmixOFghcA>?		Mlu5bY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M2qwdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OEC3OVA5Lz5{M{iwO\|UxQDxxYU6=
HepG2	NF\zTpBHfW6ldHnvckBCe3OjeR?=	NWDwS49LOC13MDFOwG0>	NXmxOJdXOjRiaB?=		M13CRolvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZicEO4JIRwf26\|dILlZY0heHKxdHXpcpMhVUGSS1HQT\|ItKEGWRkKsJG1UUzFiYX7kJGhUWDJ5IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MlPEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6MEe1NFgoRjJ\|OEC3OVA5RC:jPh?=
BEAS-2B	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\UNVAh\|ryP	NUXyPZU3OzBibXnu		MU\y[ZZmenOnczD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkhcW6mdXPl[EBjgSCKQ1m=	MojWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
BEAS-2B	MkTSR5l1d3SxeHn0fUBCe3OjeR?=	NYezWW97OTBizszN	MoTBN\|AhdWmw		NX7a[ZB6cW6qaXLpeIVlKHSqZTDpcoNz\WG\|ZTDpckBNTEhiYX7kJGlNNThiZYjwdoV{e2mxbh?=	NF[5Rog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e4OFA{PCd-MkO3PFQxOzR:L3G+
BEAS-2B	NWKwfpJjTnWwY4Tpc44hSXO\|YYm=	NXjET2ZnOTBizszN	MWCzNEBucW5?		M33EN4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHPhd5Bie2VvMzygRoFlKGGwZDDmZZM>	MlTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OESwN\|QoRjJ\|N{i0NFM1RC:jPh?=
H9c2	MUHGeY5kfGmxbjDBd5NigQ>?	NHjr[3QxNjBzL{CuNU8yKM7:TR?=	NFHIfpMyKGh?		NXrWSnl4[XS2ZX71ZZRmeyCWTl[t{tEucW6mdXPl[EBOVVBvOTDlfJBz\XO\|aX;uMEBuWk6DIHzleoVteyxiYX7kJJBzd22xdHXyJIFkfGm4aYT5	MnfoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5N{SyOVIoRjJ\|N{e0NlUzRC:jPh?=
H9c2	Mk\CSpVv[3Srb36gRZN{[Xl?	NHrnUlEyKM7:TR?=	NVjCVYszOSCq		NYXv[HZoemWmdXPld{BVVkZvzsGg[Ilz\WO2bImgd5RqdXWuYYTl[EBxOzhiTVHQT{BxcG:\|cHjvdplt[XSrb36=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd5NEK1Nkc,OjN5N{SyOVI9N2F-
U937	NX;EbYJRTnWwY4Tpc44hSXO\|YYm=	NXP4eXZyOTEEoN88UeKh	NETxRVEyKGh?		M3X1SIFjem:pYYTld{B1cGViY3Hm[oVqdmViZX\m[YN1KG:wIF3LVE0yKGGwZDDQVFJC[87zIH3SUmEhfHKjboPjdolxfGmxbnHsJIxmfmWucx?=	MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEezPFcoRjJ\|N{C3N\|g4RC:jPh?=
U937	MkW3SpVv[3Srb36gRZN{[Xl?	NYHiTmY5OTEEoN88UeKh	M4jTUVEhcA>?		M3;aPIFjem:pYYTld{Bk[W[oZXnu[U1qdmS3Y3XkJG1MWC1zIHTve44uemWpdXzheIlwdiCjbnSgVHAzSWQQsTD1dE1z\We3bHH0bY9v	MkDTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MEezPFcoRjJ\|N{C3N\|g4RC:jPh?=
U937	M{S4TmZ2dmO2aX;uJGF{e2G7	MYOxNOKh\|ryPwrC=	MlLnNUBp		MWHzeZBxemW\|c3XzJIMuUnWwIHHu[EBEWkWEIIDoc5NxcG:{eXzheIlwdiCrbjDjZYZn\WmwZT30doVifGWmIHPlcIx{yqB?	NUjXXGlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3NFc{QDdpPkKzO\|A4Ozh5PD;hQi=>
A549	MWLGeY5kfGmxbjDBd5NigQ>?	NXLkTVgxOC5\|L{OvN\|Ah\|ryP	NYSxW5ZrOSCq		MYrzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW\|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6ME[3OEc,OjN4OEC2O\|Q9N2F-
A549	MWTGeY5kfGmxbjDBd5NigQ>?	MofYNVDDqM7:TdMg	NE[0XmIxNTNyIH3pci=>		M{LBV4lvcGmkaYTzJGFVWM7\|UzDpcoR2[2WmIIC0Nk9xPDRiTVHQT{BidmRicEO4JG1CWEticHjvd5Bpd3K7bHH0bY9v	MnzzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEC2O\|QoRjJ\|NkiwOlc1RC:jPh?=
A549	NXr4[mh6TnWwY4Tpc44hSXO\|YYm=	MVexNOKh\|ryPwrC=	MVexJIg>		NWDjd2RPcW6qaXLpeJMhSVSSzsPTJIlv\HWlZXSgUmYu\|rqEIIC2OUB{fWK3bnn0JJBpd3OyaH;yfYxifGmxbjDhcoQhVkZvzsrCJJBzd22xdHXyJIFkfGm4aYT5	M1GxO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkiwOlc1Lz5{M{[4NFY4PDxxYU6=
A549	NV7VWIROTnWwY4Tpc44hSXO\|YYm=	NET2e\|EyOMLizszNxsA>	NGPH[VcyKGh?		Mn\tdoVlfWOnczDBWHDPu1Nvc4TpcZVt[XSnZDDjVGxCOiCyaH;zdIhwenmuYYTpc47DqA>?	NGD1d249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NFY4PCd-MkO2PFA3PzR:L3G+
A549	MVrGeY5kfGmxbjDBd5NigQ>?	M2j0clExyqEQvF5CpC=>	M1nGSFEhcA>?		NV3XWXpbemWmdXPld{BCXFEQs2Ot[Y5p[W6lZXSg[Y57gW2jdHnjJIFkfGm4aYT5JI9nKGOSTFGyxsA>	NU\O[oZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA3PzRpPkKzOlgxPjd2PD;hQi=>
PC12	MlPySpVv[3Srb36gRZN{[Xl?	NWTlZ\|I3OTBxMkCvOFAh\|ryP	MXKxxsBp		MmHObY5pcWKrdIOgTm5MKGGwZDDwN\|g>	NWO2cJlzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFQ{PTdpPkKzOVg1OzV5PD;hQi=>
HK-2	MXnBdI9xfG:\|aYOgRZN{[Xl?	MYGyNOKh\|ryP	M{jH[\|I1KGh?		M{PlWYlvcGmkaYTzJGVTUyCjbnSgdFM5VUGSSx?=	M{\kUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUSzNVUyLz5{M{W0N\|E2OTxxYU6=
H9c2	MkK2SpVv[3Srb36gRZN{[Xl?	Ml;MNeKh\|ryP	M{D3cFEhcA>?		M1v6SpJm\HWlZYOgWG5HNc7zLXnu[JVk\WRiTV3QMVkhdVKQQTDs[ZZmdHNiYX7kJJBzd22xdHXyJIFkfGm4aYT5	NW[1XoxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVM3QTlpPkKzN\|U{Pjl7PD;hQi=>
H9c2	M{SzbGZ2dmO2aX;uJGF{e2G7	NGLkb3kyyqEQvF2=	MVKxJIg>		NY\sVWZHemWmdXPld{BVVkZvzsGt[Y5p[W6lZXSgRXAuOSCycn;tc5RmeiCjY4Tpeol1gQ>?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN3M{[5PUc,OjN\|NUO2PVk9N2F-
H1650	NWe2fHZ{TnWwY4Tpc44hSXO\|YYm=	M2XybFExyqEQvF5CpC=>	NW\QWXg5OSCq	M2rKV2ROW09?	NFK5R21l\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:\|ZXVCpINmdGy\|	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Mki2PVYoRjJ\|MkK4Olk3RC:jPh?=
H1703	MlfFSpVv[3Srb36gRZN{[Xl?	NG\GOJUyOMLizszNxsA>	MnG2NUBp	MXTEUXNQ	MYTk[YNz\WG\|ZYOgZo91cCCycn;0[YlvKGGwZDDtVm5CKGyndnXsd{Bw\iCHUlPDNUBqdiCyYXPsbZRigGWuLXX4dI9{\WUEoHPlcIx{	NIHo[HQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFY6Pid-MkOyNlg3QTZ:L3G+
H1650	NHHDTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL2bWl{OTEEoN88UeKh	NGHaTXAyKGh?	MnjWSG1UVw>?	MUnlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6	MlGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Mki2PVYoRjJ\|MkK4Olk3RC:jPh?=
H1703	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXSSnVkOTEEoN88UeKh	M2qwO\|EhcA>?	NFXMNY5FVVOR	NW[5fFFE\W6qYX7j[ZMheGGlbHn0ZZhmdC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=	NFTORY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{KyPFY6Pid-MkOyNlg3QTZ:L3G+
medulloblastoma cells	MlLCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				MnPJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCvZXT1cIxw[myjc4TvcYEh[2WubIOgbIFz[m:{aX7nJIhmfGW{b4r5[492eyCydHPoNUBo\W6nIHL5JG1VXCCjc4PhfUwhTUN3MDC9JFMvODB4IN88UU4>	M4DXdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEG3OlMyLz5zN{SxO\|Y{OTxxYU6=
neural precursor cells	MmjjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?				NV7iSJViSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDu[ZVz[WxicILlZ5Vze2:{IHPlcIx{KGK7IF3UWEBie3OjeTygSWM2OCB;IEiuNFY{KM7:TT6=	NUi0[ZoxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NVc3OzFpPkG3OFE4PjNzPD;hQi=>
RAW264.7	M4XLcGFvfGmrbn\sZY1u[XSxcomgZZN{[Xl?		MVmxNEBucW6\|		NX2zcnRbSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBqdiCvb4Xz[UBTSVd{NkSuO{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJG5QKHC{b3T1Z5Rqd25iaX7jeYJifGWmIH\vdkAyOCCvaX7zJJBzcW:{IITvJGxRWy2laHHscIVv\2VibXXhd5Vz\WRiYX\0[ZIhOThiaILzJIJ6KEe{aXXzd{Bu\XSqb3SsJGlEPTBiPTCxOkDPxE1w	NWHSPHRwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N\|E4QThpPkKyPFMyPzl6PD;hQi=>
BL21(DE3)	MYTGeY5kfGmxbjDhd5NigQ>?		M4LieVYxKG2rboO=		NWrEO4l3UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKEKURESg[ZhxemW\|c3XkJIlvKEW\|Y3jldolkcGmjIHPvcIkhSkx{MTjESVMqKGOnbHzzJJV{cW6pIHLpc5RqdnmuYYTl[EBpcXO2b37lJGg1KHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDZyIH3pcpMh[nliQXzwbIFU[3KnZX6gZZN{[XluIFnDOVAhRSB\|LkSg{txONg>?	MluzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOUW3NlMoRjJ6MUm1O\|I{RC:jPh?=
RAW264.7	Mn75SpVv[3Srb36gZZN{[Xl?				NEXTZYRRem:2ZXP0bY9vKGGpYXnud5QhSmGlaXzseZMh[W62aILhZ4l{KHC{b4TlZ5RqfmViYX70bYdmdiCjbnSgcIV1cGGuIITvfIlvNWSrcHj0bIVzcWFidH;4bY4h[2irbXXybYMheHKxdHXpckBu\WSrYYTl[EBkgXSxdH;4bYNqfHliaX6gcY92e2ViUlHXNlY1NjdiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJk>	NInBb2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{S4OVUxPCd-MUe0PFU2ODR:L3G+
A673	MVnxTHRUKGG\|c3H5				MnnUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	M1TxTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	NYXPZoNGeUiWUzDhd5NigQ>?				M4jpZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	M2fKTpFJXFNiYYPzZZk>				MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	NFXvXYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NXLLWFRDeUiWUzDhd5NigQ>?				M3j6eJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	Mle4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NHrwWWNyUFSVIHHzd4F6				NGHxXJhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	NGHuTFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M2DiXJFJXFNiYYPzZZk>				NGLNdYtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	NX7jS4Y2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NVu2[nFSeUiWUzDhd5NigQ>?				MV\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NE\tfXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MWnxTHRUKGG\|c3H5				MY\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	NFrwSZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MVXxTHRUKGG\|c3H5				M173dZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN?	M1XiTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MVLxTHRUKGG\|c3H5				MnXJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	Mn7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NU\pU29CeUiWUzDhd5NigQ>?				M331NJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NW\TcI9yeUiWUzDhd5NigQ>?				MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	M4fwXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	MVLxTHRUKGG\|c3H5				NFj2eItyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDNyIHPlcIx{	NFTMVpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	M4jUUZFJXFNiYYPzZZk>				MkLKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{	NXS0VoFZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NHXTdYZyUFSVIHHzd4F6				NW[2[VY2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NXfW[JhMeUiWUzDhd5NigQ>?				MlexdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NIPGWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	MU\xTHRUKGG\|c3H5				MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORlE3PDNiY3XscJM>	NITBTpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NHr0ZYtyUFSVIHHzd4F6				NEX1Zm9yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	NWDnSG5DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	NXXJXnp5eUiWUzDhd5NigQ>?				M3e4epFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
TC32	M1fmcZFJXFNiYYPzZZk>				MmPCdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	NV\2PGdZeUiWUzDhd5NigQ>?				MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzz	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; PubMed: 26844273 EBioMedicine CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. pJNK1 / pJNK2 / JNK1 / JNK2 ; PubMed: 18222647 Cell Signal A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described.	26844273 18222647
Immunofluorescence	p-p38 / MMP9; PubMed: 24479681 Mol Cancer Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.	24479681
Growth inhibition assay	Cell viability ; PubMed: 26844273 EBioMedicine Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).	26844273

体内研究

SB 202190通过抑制p38减弱了由人脊髓灰质炎IgG（PV-IgG）在被动转移小鼠模型中诱发的水泡形成^[5]。在脓毒症内毒素模型中，与对照组相比，经SB 202190处理可显著提高存活率^[8]。

激酶实验： ^[1]	- 合并体外酶活检测: p38α 和 p38β 溶解在25mM的Tris - HCl缓冲液中，PH 7.5，含0.1mM EGTA，髓鞘碱性蛋白（0.33毫克/毫升）作为底物。人工操作条件用50μL [γ-³³P]ATP于30 °C孵育10分钟；Biomek 2000自动化工作站用25μL [γ-³³P]ATP在96孔板室温孵育40分钟。ATP和乙酸镁浓度分别为0.1mM和10mM。所有检测都用MgATP起始。人工检测将孵育液滴到磷酸纤维素纸上，浸泡在50mM磷酸中。用5μL磷酸终止反应，后将孵育液点滴在P30过滤垫上。滤膜在50mM磷酸中漂洗四次以去除ATP，在用丙酮（人工孵育）或甲醇（工作站孵育）处理后，干燥并用放射性计量。
细胞实验： ^[2]	- 合并 Cell lines: Jurkat, 和 HeLa细胞 Concentrations: 溶解于DMSO, 终浓度~50 μM Incubation Time: 24 小时 Method: 细胞血清饥饿后，用不同浓度SB 202190处理24小时。用台盼蓝或PI染色后经流式细胞仪分析，以检测细胞活力。凋亡细胞核用H33258染色。 (Only for Reference)
动物实验： ^[5]	- 合并 Animal Models: C57BL/6J 小鼠皮内注射无菌的对照IgG或人脊髓灰质炎IgG做对比。 Dosages: 12.5 μg Administration: 皮内注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	66 mg/mL (199.19 mM)
	Ethanol	12 mg/mL (36.21 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%H2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download SB202190 (FHPI) SDF

分子量	331.34
化学式	C₂₀H₁₄N₃OF
CAS号	152121-30-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

选择性强的p38 MAPK抑制剂

BIRB 796 (Doramapimod) : p38α-selective, Kd=0.1 nM.
活性最高的p38 MAPK抑制剂

Skepinone-L ^New : p38α-MAPK, IC50=5 nM.
用于临床的p38 MAPK抑制剂

VX-702 : Phase II for Rheumatoid Arthritis.
最新的p38 MAPK抑制剂

Skepinone-L ^New : Selective p38α-MAPK inhibitor with IC50 of 5 nM.

研究领域

产品类型

定制您的化合物库

SB202190 (FHPI)

客户使用Selleck生产的SB202190 (FHPI)发表文献110篇：

产品安全说明书

p38 MAPK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download SB202190 (FHPI) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

相关p38 MAPK产品